Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has received an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $40.86.

A number of equities analysts have recently issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, October 15th. Stifel Nicolaus initiated coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They issued a “buy” rating and a $36.00 price objective for the company. HC Wainwright restated a “buy” rating on shares of Lyell Immunopharma in a report on Friday, September 11th. Finally, B. Riley Financial assumed coverage on Lyell Immunopharma in a report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 target price for the company.

Lyell Immunopharma Price Performance

Shares of Lyell Immunopharma stock opened at $11.04 on Tuesday. Lyell Immunopharma has a 1 year low of $7.20 and a 1 year high of $45.00. The firm’s 50-day moving average is $11.02 and its two-hundred day moving average is $16.90. The stock has a market cap of $270.48 million, a price-to-earnings ratio of -0.86 and a beta of -0.03.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The business had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. On average, equities analysts expect that Lyell Immunopharma will post -7.16 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in LYEL. venBio Partners LLC bought a new stake in Lyell Immunopharma during the second quarter valued at about $4,744,643. Opaleye Management Inc. grew its stake in Lyell Immunopharma by 334.9% in the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock valued at $4,834,000 after purchasing an additional 264,928 shares during the last quarter. Renaissance Technologies LLC grew its stake in Lyell Immunopharma by 194.8% in the first quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after purchasing an additional 76,921 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Lyell Immunopharma in the first quarter worth about $959,000. Finally, Bank of America Corp DE raised its holdings in Lyell Immunopharma by 314.2% in the first quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock worth $668,000 after purchasing an additional 25,276 shares in the last quarter. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.